BMS 354825 Dasatinib Tyrosine Kinase Inhibitor Cas 302962-49-8
BMS 354825 Dasatinib Tyrosine Kinase Inhibitor Cas 302962-49-8
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Dasatinib |
Purity:98% min |
|
CAS NO:302962-49-8 |
Solubility:DMSO35.35 mg/mL (72.44 mM) |
|
Molecular Formula:C22H26ClN7O2S |
Package:Package according to customer requirements |
|
Molecular Weight:488.006 |
Storage:Store at -20℃ |
Quality control
COA
Remarks
Dasatinib, previously known as BMS-354825, is a cancer drug. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.
Properties:
Appearance & Physical State: pale-yellow solid
Density: 1.408g/cm3
Melting Point: 275-286C
Related Products
Afatinib dimaleate; Neratinib; Bosutinib; Bosutinib Intermediates; Bosutinib Monohydrate; Saracatinib; NVP-BHG712; PP1; PP2; A-966492; G007-LK; SU6656; Tirbanibulin; TPX-0005; Afatinib
References
[1].O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. C
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.